ALK-Abelló A/S (CPH:ALK.B)

Denmark flag Denmark · Delayed Price · Currency is DKK
227.80
-1.60 (-0.70%)
At close: Dec 5, 2025
38.56%
Market Cap 50.74B
Revenue (ttm) 6.08B
Net Income (ttm) 1.10B
Shares Out 221.19M
EPS (ttm) 4.97
PE Ratio 46.11
Forward PE 37.88
Dividend n/a
Ex-Dividend Date n/a
Volume 78,681
Average Volume 232,888
Open 229.40
Previous Close 229.40
Day's Range 227.00 - 230.00
52-Week Range 130.70 - 237.60
Beta 0.70
RSI 55.39
Earnings Date Nov 13, 2025

About ALK-Abelló

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mites, grass and tree pollen, ragweed, Japanese cedar, and food. It also provides consumer healt... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1923
Employees 2,753
Stock Exchange Copenhagen Stock Exchange
Ticker Symbol ALK.B
Full Company Profile

Financial Performance

In 2024, ALK-Abelló's revenue was 5.54 billion, an increase of 14.78% compared to the previous year's 4.82 billion. Earnings were 815.00 million, an increase of 67.70%.

Financial Statements

News

Alk-Abello AS (AKBLF) Q3 2025 Earnings Call Highlights: Robust Revenue and Earnings Growth Amid ...

Alk-Abello AS (AKBLF) Q3 2025 Earnings Call Highlights: Robust Revenue and Earnings Growth Amid Strategic Expansions

22 days ago - GuruFocus

Alk-Abello AS (AKBLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved Margins

Alk-Abello AS (AKBLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved Margins

1 year ago - GuruFocus